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ABSTRACT 
 
Carl F Raetzsch 
The Mechanism of Lipopolysaccharide Inhibition of Glucose Production and Its Significance 
to Cancer 
 (Under the Direction of Terry P Combs) 
 
Nuclear factor kappa B (NFκB) induces insulin resistance in mammals, possibly 
representing a counter-regulatory response by which the host escapes NFκB-induced 
hypoglycemia. However, the underlying mechanism remains unclear. To identify the 
mechanism of NFκB-induced hypoglycemia, we measured hepatocyte glucose production 
and whole-body glucose utilization in mice. Inhibition of glucose production and utilization 
by lipopolysaccharide depended on toll-like receptor 4, myeloid differentiation factor 88 and 
NFκB, while tumor necrosis factor alpha and the insulin signaling intermediate 
phosphatidylinositol 3-kinase were unnecessary. Taxol, a widely-used cancer drug, also 
activates toll-like receptor 4 and several of its downstream intermediates, but its mechanism 
is unclear. To determine whether Taxol destroys tumors by decreasing glucose availability, 
we measured glucose utilization in vitro. Taxol decreased glucose utilization in MCF7 cells. 
Additionally, Taxol increased plasma adiponectin, a biomarker of low fasting glucose 
utilization, in treatment-responsive breast cancer patients. This biomarker could predict the 
effectiveness of Taxol in individuals. 
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CHAPTER I – BACTERIAL LIPOPOLYSACCHARIDE AND GLUCOSE 
METABOLISM 
 
 
 
 
INTRODUCTION 
 
Current View of LPS Mechanism Includes IL-1α/β 
Lipopolysaccharide (LPS) from Gram-negative bacteria causes hypoglycemia in 
mammals. However, the underlying mechanism and its significance to insulin action remain 
vague. LPS does not induce hypoglycemia by elevating insulin (1). Instead, the current view 
is that LPS induces hypoglycemia by elevating circulating interleukin-1 beta (IL-1β) and 
tumor necrosis factor alpha (TNFα) (2). LPS cannot induce hypoglycemia in IL-1α-/- and IL-
1β-/- double knockout mice, so LPS induction of hypoglycemia clearly depends on IL-1α or 
IL-1β (3). 
Insulin Resistance as a Counter-Regulatory Response 
Since mortality from an otherwise lethal injection of LPS can be averted by injection 
of glucose and since insulin is the main inhibitor of glucose production by the liver, liver 
insulin resistance may arise as a counter-regulatory response to rescue the host from 
hypoglycemia during infection (4,5). Based on this hypothesis, insulin resistance may be a 
more effective counter-regulatory mechanism if LPS and insulin inhibit glucose production 
by separate pathways. This way, circulating glucose levels could be restored without 
compromising every immune response triggered by LPS. Therefore, LPS injection or Gram-
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negative bacteria infection may impair the ability of insulin to lower glucose production. 
Whether LPS and insulin inhibit glucose production by separate pathways is currently 
unknown. 
TNFα, Insulin and PI3K Action 
Insulin can lower glucose by suppressing the expression of genes like glucose 6-
phosphatase (G6Pase) through phosphatidylinositol 3-kinase (PI3K) (6). Insulin activation of 
PI3K causes a transient increase of phosphatidylinositol-3,4,5-phosphate in cell membranes. 
This activates protein kinase B (PKB). Activated PKB suppresses G6Pase mRNA expression 
after translocating to the nucleus and phosphorylating forkhead transcription factor Foxo1 
(FKHR), a member of the Forkhead/winged helix family of transcription factors (7). In 
support of the view that insulin and LPS inhibit glucose production by different pathways, 
TNFα inhibition of glucose production by hepatoma cells is not impaired by the 
pharmacologic inhibitor of PI3K, LY294002 (8). 
G6Pase and NFκB 
LPS, IL-1 and TNFα  can cause hypoglycemia by lowering the expression of G6Pase 
mRNA in the liver (9-11). G6Pase is rate limiting as the last step in glucose production by 
gluconeogenesis or glycogenolysis. The suppression of G6Pase by TNFα depends on the 
activation of nuclear factor kappa B (NFκB). NFκB is activated by phosphorylation and 
degradation of the inhibitor of NFκB (IκB) and translocation of NFκB subunits p50/p65 to 
the nucleus. The suppression of G6Pase by TNFα can be inhibited by a dominant-negative 
IκB mutant (8). Whether LPS inhibition of glucose production depends on NFκB has never 
been tested by a dominant-negative IκB mutant. 
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Numerous observations suggest that LPS-induced hypoglycemia depends on TNFα. 
For example, (a) LPS does not induce hypoglycemia in C3H/HeJ mice which fail to show an 
LPS induced increase in TNFα, (b) LPS induction of hypoglycemia coincides with LPS 
induction of TNFα and (c) injection of recombinant TNFα triggers hypoglycemia in a 
manner similar to the injection of LPS (12-14). The view that LPS induces hypoglycemia 
through TNFα was challenged by observations that the injection of antibodies against TNFα 
can block LPS induction of TNFα but not hypoglycemia (15,16). However, these studies did 
not exclude the possibility that LPS induces hypoglycemia through TNFα because injected 
antibodies, while clearly capable of neutralizing the elevation of circulating TNFα, might fail 
to block the paracrine effects of TNFα. This might be the case if LPS induced TNFα 
secretion from Kupffer cells in the liver and, thereby, inhibited glucose production of 
neighboring hepatocytes. 
LPS and TLR4-MyD88 
LPS stimulates TNFα and IL-1 in cells of myeloid origin by binding to the Toll-like 
receptor-4 (TLR4), an integral membrane protein that is similar to Toll in Drosophila 
melanogaster in both amino acid sequence and immune function (17,18). Mammalian Toll-
like receptors recognize conserved microbial components that are absent in mammals. LPS 
mediates its effects through the interaction of the Toll/interleukin-1 receptor (TIR) domains 
on TLR4 and either myeloid differentiation factor 88 (MyD88) or TIR domain-containing 
adaptor inducing IFN-β (TRIF) (19-21). To our knowledge, it has never been determined 
whether LPS induces hypoglycemia through TLR4-MyD88 in TLR4-/- and MyD88-/- mice. 
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Summary 
Our experiments provide further insight into the independent mechanisms that cause 
hypoglycemia in response to insulin or Gram-negative bacterial infection. In brief, we 
determined (1) whether LPS and insulin inhibit glucose production by independent pathways 
by inhibiting PI3K in hepatoma cells; (2) whether NFκB activation is required for LPS-
mediated inhibition of glucose production using a dominant-negative IκB mutant that inhibits  
NFκB in hepatoma cells; (3) whether TLR4, MyD88 and TNFα are necessary for LPS to 
induce hypoglycemia in knockout mice; and (4) whether the rates of glucose utilization and 
glucose production are decreased during the hypoglycemic state by measuring the 
disappearance of a glucose tracer in mice. The significance of the pathway we describe is 
reviewed in the Discussion. 
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RESULTS 
 
LPS and Insulin Inhibit Glucose Production by Different Pathways  
In order to demonstrate that LPS and insulin inhibit glucose production by separate 
pathways, we performed three experiments. McArdle 7777 rat hepatoma cells were either 
untreated or primed with LY294002 (33 µM) and exposed to LPS (2.5 µg/ml) and/or insulin 
(10 µM). LY294002, a broad PI3K inhibitor, did not inhibit LPS-induced suppression of 
glucose production (Figure 1) (22). McArdle 7777 cells were either untreated or primed by 
LPS (2.5 µg/ml) and were untreated or exposed to LY294002. Exposure to LY294002 caused 
a significant increase in glucose production in both LPS-primed and untreated McArdle 7777 
cells (data not shown). TLR4+/+ and TLR4-/- mice were injected with 1.0 U insulin (per kg 
body weight) and glucose was measured at 15, 30, 45, 60, 90 and 120 minutes. The glucose 
profile after insulin injection was similar between TLR4+/+ and TLR4-/- mice (Figure 2). 
Therefore, LPS and insulin inhibit glucose production by separate pathways. 
Inhibition of Glucose Production by LPS Depends on NFκB 
The McArdle RH7777 cell line was used to determine whether LPS inhibition of 
glucose production depends on NFκB. Hepatoma cells were transduced with retroviral vector 
encoding green fluorescent protein (GFP) only or both GFP and a degradation resistant IκB 
mutant that blocks NFκB activation. Transduction and mRNA expression of the dominant-
negative IκB mutant was confirmed by PCR (Figure 3A). Inhibition of glucose production by 
2.5 µg/ml LPS was blocked in hepatoma cells transduced with the retroviral vector encoding 
the dominant-negative IκB mutant (Figure 3B). Therefore, LPS inhibition of glucose 
production depends on the activation of NFκB. Furthermore, LPS activates translocation of 
NFκB to the nucleus of liver cells in mice (Figure 4). 
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FIGURE 1. Lipopolysaccharide (LPS) inhibition of glucose production does not depend upon 
PI3K in vitro. (A) McArdle 7777 were untreated (CTL), exposed to 10 µM insulin, or primed 
with 33 µM LY294003, a competitive inhibitor of phosphatidylinositol 3-kinase. Cells were 
then exposed to LPS (2.5 mg/ml) or remained free of LPS. (B) Cell cultures isolated from rat 
liver  were  exposed  to  2.5 µg/ml  LPS and glucose secretion into the media was measured. 
*  Significant  difference  between  LPS  and  non-LPS  within  treatment  (n=3;  p<0.05).   
**  Significant difference from non-LPS control (n=3; p<0.05). Error bars represent SEM. 
A 
B 
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FIGURE 2. The glucose profile after insulin injection is similar between toll-like receptor 4 
knockout (TLR4-/-) and wild-type (TLR4+/+) mice. TLR4+/+ and TLR4-/- mice were injected 
with 1.0 U insulin per kg body weight. Glucose was measured at 15, 30, 45, 60, 90 and 120 
minutes after injection. No significant difference was found between TLR4+/+ and TLR4-/- 
mice (n=5; p>0.05). Error bars represent SEM. 
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FIGURE 3. Lipopolysaccharide inhibition of glucose production depends on nuclear factor 
kappa B (NFκB). (A) McArdle RH7777 cells were transduced with retroviral vector 
encoding either green florescent protein (GFP) only or both GFP and a degradation resistant 
inhibitor of NFκB mutant (IκB-SR) that blocks NFκB activation. Transduction and mRNA 
expression of the dominant-negative IκB mutant was confirmed by PCR. (B) Inhibition of 
glucose production by 2.5 µg/ml LPS was blocked in hepatoma cells by IκBα-SR. * 
Significant difference between LPS and non-LPS (n=3; p<0.05). Error bars represent SEM. 
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FIGURE 4. Lipopolysaccharide (LPS) induces nuclear factor kappa B (NFκB) activation in 
mouse liver. Mice were injected with LPS 4 or 10 hours before sacrificing or left untreated. 
Fresh livers were snap frozen in liquid nitrogen and homogenized. Nuclei were extracted and 
nuclear NFκB was visualized by electrophoretic mobility shift assay. All controls used 
extracts from 10 h LPS treated mice. Supershifts for p65 and p50 subunits of NFκB were 
used to validate binding of probe. Rabbit anti-IgG was used as positive control. Mutant 
UV21 consensus sequence for NFκB was used as a competitive inhibitor. Three replicates 
were performed. 
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LPS-Induced Hypoglycemia Depends on TLR4 and MyD88 but not TNFα 
To determine whether LPS-induced hypoglycemia depends on TNFα, TLR4 and 
MyD88, we used TNFα-, TLR4- and MyD88-null knockout mice, respectively. Wildtype 
(TNFα+/+) and TNFα-null (TNFα-/-) mice were injected with 0.5 LPS (mg/kg body weight). 
TNFα was elevated by LPS injection in TNFα+/+ mice, but not in TNFα-/- mice (Figure 5A). 
TNFα+/+ and TNFα-/- mice showed similar reductions in plasma glucose after LPS injection 
(Figure 5B). TLR4+/+ and TLR4-/- mice were injected with various doses of LPS and glucose 
was measured 4 hours after injection. Plasma glucose was reduced in TLR4+/+ but remained 
unchanged in TLR4-/- (Figure 6). MyD88+/+ and MyD88-/- mice were injected with 0.5 mg 
LPS (per kg body weight) and plasma glucose was measured 1 to 4 hours after injection. 
Glucose was reduced in MyD88+/+ mice but not in MyD88-/- mice (Figure 7). These results 
support the dependence of LPS-induced hypoglycemia on TLR4 and MyD88 but not on 
TNFα.  
LPS Lowers Utilization and Production of Circulating Glucose 
The effect of LPS on the utilization and production of circulating glucose was 
determined in wild-type mice injected with 0.5 mg LPS per kg body weight or saline. Eight 
hours after injection, while circulating levels of glucose were steady, LPS and saline treated 
mice received trace amounts of 3H-glucose by intravenous injection. Because circulating 
glucose levels are stable 8 hours after LPS or saline injection  (Figure 8A),  the  utilization  of 
circulating glucose equals the production of circulating glucose.  LPS lowered the utilization 
and production of circulating glucose (Figure 8B). 
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FIGURE 5. LPS-induced hypoglycemia does not depend on TNFα.  (A) TNFα+/+ and  
TNFα-/- mice were injected with 0.5 mg LPS per kg body weight (black bars) or saline (white 
bars). TNFα was measured 8 hours after LPS injection. (B) TNFα+/+ and TNFα-/- mice were 
injected with 0.5 mg LPS per kg body weight (black bars) or saline (white bars). Glucose was 
measured 8 hours after LPS injection. * Significant difference between LPS and saline 
injection or wild-type and mutant mice (n=5-6; p<0.05). Error bars represent SEM. 
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FIGURE 6. LPS-induced hypoglycemia depends on TLR4. TLR4+/+ (black bars) and TLR4-/- 
(white bars) mice were injected with indicated doses of LPS. Glucose was measured 4 hours 
after injection. * Significant difference between wild-type and mutant mice (n=5-6; p<0.05). 
Error bars represent SEM. 
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FIGURE 7. LPS-induced hypoglycemia depends on MyD88. MyD88+/+ (black bars) and 
MyD88-/- (white bars) mice were injected with 0.5 mg LPS (per kg body weight). Plasma 
glucose was measured at 1, 2, 3 and 4 hours after injection. Results represent the mean ± 
SEM from n = 5 mice per group. * Significant difference between wild-type and mutant mice 
(n=5-6; p<0.05). Error bars represent SEM. 
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FIGURE 8. LPS-induced hypoglycemia is mediated by the inhibition of glucose production. 
(A) Wild-type mice were injected with 0.5 mg LPS per kg body weight.  Glucose was 
measured 4, 8, 12 and 24 hours after injection. * Significant difference from 0 hours. (B) 
Eight hours after injection, while circulating levels of glucose were steady, LPS and saline 
injected mice received trace amounts of 3H-glucose by intravenous injection. The 
disappearance of 3H-glucose was used to determine the utilization of circulating glucose. * 
Significant difference from control (n=6; p=0.03). Error bars represent SEM. 
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DISCUSSION 
 
Insulin Resistance as a Counter-Regulatory Response to LPS 
A 3-compartment model can illustrate the LPS-induced decrease in glucose utilization 
and glucose production (Figure 9). The two 3-compartment models shown represent a high 
rate of glucose utilization and production in control mice (top) and a low rate of glucose 
utilization and production in LPS injected mice (bottom). Our data suggest that insulin 
resistance may appear as a counter-regulatory response to LPS inhibition of glucose 
production through NFκB. In other words, insulin resistance may be a counter-regulatory 
response to hypoglycemia by increasing glucose production. A feedback loop may detect 
LPS-induced hypoglycemia and drive down hepatic insulin sensitivity, allowing glucose 
production to increase and the host to escape the lethal effects of hypoglycemia (Figure 10). 
Evidence Supporting Increased LPS in Diabetes 
We currently do not know the mechanism by which hypoglycemia is detected, 
triggering insulin resistance. However, circulating levels of LPS are increased in type 2 
diabetes (23). Gut-derived bacteria may represent a significant source of LPS, promoting 
chronic subclinical levels of inflammation (23-25). 
PI3K Interactions with NFκB 
There are many examples of PI3K affecting NFκB action in myeloid cells. LPS 
induction of IL-1 is blocked by PI3K inhibitors in macrophages (26). Treatment of 
monocytes with genistein and herbimycin A, a protein tyrosine kinase-specific inhibitor, 
blocked activation of NFκB by LPS (27). Inhibition of the PI3K pathway in monocytes 
enhanced LPS-induced activation of the p38 MAPK, JNK, and ERK1/2 pathways, whereas 
activation  of  PI3K-PKB  pathway  limited  TNFα  expression  (28).  Negative  regulation  of 
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FIGURE 9. The change in glucose metabolism induced by lipopolysaccharide (LPS) 
injection can be illustrated with by a 3-compartment model. The 2 models show a high rate 
of glucose utilization and production in control mice (top) and a low rate of glucose 
utilization and production in LPS injected mice (bottom).  
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FIGURE 10. Conceptual scheme showing the development of insulin resistance in 
hepatocytes as a counter-regulatory response that allows the host to escape hypoglycemia 
following lipopolysaccharide (LPS) exposure. Initially, insulin signaling is strong, 
suppressing glucose production to a normal rate (e.g. 20 mg/kg/min), while the contribution 
of LPS to this suppression is negligible. Next, upon exposure to LPS, the combined 
suppressive effects of insulin and LPS cause acute hypoglycemia. To restore glucose 
production to its normal rate, mild insulin resistance develops as a counter-regulatory 
response. Finally, LPS is cleared from the system, but insulin resistance persists, resulting in 
an unregulated increase in glucose production (e.g. 40 mg/kg/min).  
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NFκB by PI3K suppresses the production of iNOS and TNFα (29). 
LPS Inhibition of Glucose Production is Independent of PI3K 
Inhibition of glucose production by LPS did not depend on signaling of PI3K. This 
observation suggests that the inhibition of glucose production by LPS and insulin may occur 
by independent signaling mechanisms. The absence of a PI3K effect on LPS inhibition of 
glucose production does not apply to every LPS-mediated effect. Furthermore, LPS or insulin 
alone did not detect a significant decrease in glucose production, but exposure to both 
reagents simultaneously caused a significant decrease. This additive effect supports the 
hypothesis that insulin and LPS act through separate pathways. 
LPS Inhibition of Glucose Production Depends on NFκB 
LPS inhibition of glucose production depended on NFκB in isolated hepatocytes, and 
LPS induces activation of NFκB and subsequent translocation to the nucleus in mouse liver 
in vivo. NFκB may be the only TLR4/MyD88 target that inhibits glucose production. The 
other two major TLR4/MyD88 targets are p38 mitogen-activated protein kinase and c-Jun 
NH2-terminal kinase. Both increase plasma glucose (30,31). Inducible nitric oxide synthase 
and cyclooxygenase inhibitors, such as acetylsalicylic acid, indomethacin or ibuprofen, 
interfere with NFκB inhibition of glucose production (32,33). Interestingly, cells transfected 
with IκB-SR produced less glucose even prior to LPS exposure. This suggests that chronic 
activation of NFκB may also promote glucose production. 
Findings Showing LPS Inhibition of Glucose Production Are Novel 
Evidence that LPS induces hypoglycemia in rodents by inhibiting glucose production 
is not novel (34). However, while many previous studies using techniques that maintain 
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euglycemia show that LPS increases glucose utilization, we are the first to show that 
utilization of glucose can also be lowered by LPS (35). 
TLR4 and MyD88 Required for LPS Inhibition of Glucose Production 
TLR4 represents the primary target of LPS and we link it to MyD88 and the resulting 
hypoglycemia. TLR4 and MyD88 signaling involves the sorting adaptor, TIR-associated 
protein, and other signaling intermediates. Other signaling intermediates leading up to the 
activation of NFκB, such as TLR4 and MyD88, may also be essential for LPS-induced 
hypoglycemia. 
Discussion Summary 
In summary, our results suggest that LPS can cause hypoglycemia by inhibiting 
glucose production through TLR4, MyD88 and NFκB.  Furthermore, LPS signaling does not 
affect the insulin signaling pathway directly, but chronic LPS exposure results in LPS 
tolerance (36). We propose that the pathway we describe links inflammation to insulin 
resistance. In this model, liver insulin resistance is a counter-regulatory response that can 
increase animal survival during a Gram-negative bacteria infection by alleviating 
hypoglycemia. 
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EXPERIMENTAL PROCEDURES 
 
Mice 
3-6 month old male mice of C57Bl/6 background were used to create all knockouts. 
TNFα-/- mice were obtained from the Jackson Laboratory (37). TLR4-/- and MyD88-/- mice 
were obtained from Osaka University (18,38). Mice were housed in ventilated isolator cage 
systems in a pathogen-free barrier facility at 23oC, 55% humidity on a 12-hour light/12-hour 
dark cycle. Experimental procedures were approved by the Institutional Animal Care and 
Use Committees at the University of North Carolina. 
Circulating Glucose Levels after LPS and Insulin Injection  
Food was removed at 7 am. Mice were given a single intra-peritoneal injection of 
LPS (E. coli serotype 0111:B4; Sigma) or saline at 10 am. Blood (<5µl) was gently squeezed 
out of the tail tip from a cut below the vertebrae and placed directly on a test strip attached to 
a hand-held glucose meter (One-Touch Ultra; Johnson and Johnson). Mice were weighed 
before LPS injection. Insulin (Humanlin R; Eli Lilly) was given by intra-peritoneal injection 
8 hours after LPS injection. Anesthesia and mouse restraining devices were not used. 
Utilization of Circulating Glucose 8 Hours after LPS Injection 
Mice received a single intra-peritoneal injection of LPS (0.5 mg/kg) or saline at 10 
a.m. After 8 hours, while circulating levels of glucose were stable, mice received 3H-glucose 
(D-[3-3H]glucose; Amersham Biosciences) by injection through the ophthalmic plexus. Trace 
amounts of 3H-glucose in 50-100µl saline were injected directly into the circulation of 
conscious,free moving mice. Blood samples (10-20 µl) were collected from the tail tip 3, 6, 
9, 12, 15, 18 and 21 minutes after injection for the measurement of glucose and radioactivity 
(39). 
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Isolated Hepatocyte and Hepatoma Cell Glucose Production 
Glucose production was measured in isolated hepatocytes and hepatoma cells as 
previously described (40). Freshly isolated rat hepatocytes were plated at 105 cells per well in 
a 12-well culture plate coated with rat tail collagen I (BD Biosciences). Cells were cultured 
in 25mM glucose Dulbecco’s Modified Eagle Medium (DMEM; Caisson Laboratories) 
supplemented with 10% horse serum (HS). After 4 hours, media was changed to 25mM 
glucose DMEM supplemented with 2.5% Fetal Bovine Serum (FBS) and 2.5% HS. After 8 
hours, media was changed to 5 mM glucose DMEM supplemented with 5% HS with LPS 
(2.5 µg/mL), or dimethylsulphoxide (DMSO). After 8 hours, the media was changed to 
glucose free and serum free DMEM containing 5 mM each of alanine, glycine, valine, 
sodium pyruvate and lactate (Sigma). Cells were incubated for 8 hours. Media and cell 
lysates in RIPA buffer were collected. Glucose in the media and cell culture protein were 
measured by colorimetric assays (Autokit Glucose CII; Waco and BCA Assay Kit; Pierce). 
Rat hepatoma cells (McArdle 7777) were stored in liquid nitrogen at 106 cells/ml. Hepatoma 
cells were plated at 25,000-50,000 per well. LPS (2.5 µg/mL), LY294002 (33 µM; 
Calbiochem) or DMSO were added at the indicated times and glucose production was 
measured as described for isolated hepatocytes. 
Retroviral Transduction 
The dominant-negative IκB-SR mutant construct was used to generate an IκB-SR 
fragment flanked by EcoRI and ApaI sites that was subcloned into pML2(EGFP-N1) to 
produce the IκB-SR-pML2(EGFP-N1) retroviral construct (41). HEK293 cells were 
transfected with a 3:1 ratio of IκB-SR-pML2(EGFP-N1):pCL-ECO using the Fugene 
transfection reagent and subsequently incubated in DMEM/10% FBS at 37ºC for 48 hours. 
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Media was changed to DMEM/2.5% FBS/2.5% HS. Transfected cells were placed at 32ºC 
for two days to allow for retroviral production. The virus-containing media (6 ml) was 
removed from cells and polybrene (2.67 µg) was added. The solution was centrifuged at 
3500 rpm for 5 min at room temperature. The viral supernatant (2 ml/well of 6-well plate) 
was introduced to rat hepatoma cells for 12-18 hours. The pML2(EGFP-N1) construct was 
used as a control for effects of transfection and was referred to as “GFP”. DNA and RNA 
were isolated (DNeasy and RNeasy Kits; Qiagen). RNA was used to prepare cDNA using 
random hexamers (Superscript; Invitrogen). DNA and cDNA were tested by PCR for the 
IκB-SR sequence (forward primer CTGGAATTCCAGGCG; reverse primer 
GTCGGGCCCTCATAACGTCAG). 
Nuclear Extraction and EMSA 
Nuclear extracts and EMSAs were prepared and carried out as previously described 
(42,43). Briefly, cultured cells or fresh, snap frozen livers were crushed in liquid nitrogen and 
Dounce homogenized in a 0.3 M sucrose buffer. Nuclei were isolated by layering and 
pelleting through 0.88 M and 1 M sucrose solutions. Nuclear extracts were incubated with 
32P-labeled oligonucleotide corresponding to an NFκB site on the H-2Kb gene (5'-
CAGGGCTGGGGATTCCCATCTCCCACAGTTTCACTTC-3') (Boehringer Mannheim) 
and loaded onto a 5% acrylamide/TGE gel. 
Statistics  
Significant differences among data for the insulin and PI3K experiment (Figure 1A) 
were determined using Tukey-Kramer test. Significant differences among groups for all other 
experiments were determined using a two-tailed, two-sample unequal-variance Student's t 
test. Statistical significance was established whenever p < 0.05. 
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CHAPTER II – CANCER THERAPY AND GLUCOSE METABOLISM 
 
The role of glucose metabolism in the development and progression of cancer is not 
well understood. It is well accepted that tumors are dependent upon glucose, but it is not 
known whether glucose deprivation may be responsible for some of the effects of 
chemotherapy. If glucose metabolism can affect cancer treatment and outcomes, a biomarker 
for glucose metabolism may aid in the prescription of effective therapeutic agents. 
Glucose Metabolism and Cancer 
Cancer cells undergo mitosis more rapidly than do normal cells because cancer cells 
spend less time in the G1 phase (44). As this accelerated growth and division requires an 
abundance of energy, cancer cells are greatly dependent upon anaerobic glycolysis (45-47). 
Therefore, they have increased sensitivity to glucose deprivation, which is highly cytotoxic to 
the transformed cells (48,49). Changes in energy balance that lead to obesity can increase the 
risk of breast cancer (50). Hyperglycemia, in both type-2 diabetes and non-diabetic 
hyperglycemia, increases this risk (51). Several other factors connect glucose metabolism to 
cancer, including insulin resistance, hyperinsulinemia, and insulin-like growth factor 1 (52-
56). Presently, only one clinical trial is examining the theory that reducing glucose 
production or utilization can target cancer cells (clinicaltrials.gov; identifier: NCT00096707). 
Taxanes as Chemotherapeutic Agents 
Taxanes are a family of chemotherapeutic compounds isolated from the bark of the 
pacific yew tree (57). Taxanes are now a reasonably successful standard treatment for breast 
and other cancers. These drugs mediate their effects by over-stabilizing the structural 
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microtubules of cells, hindering cell division during mitosis (58,59). By this mechanism, 
taxanes can disrupt rapidly dividing cancer cells more so than normal cells and are able to 
select against tumors. However, a significant number of cancer patients do not show 
complete tumor regression in response to taxanes. Furthermore, microtubule over-
stabilization cannot account for the entire therapeutic effect of the drugs. Other compounds 
that stabilize microtubules do not have anti-cancer effects (60). These data suggest that 
taxanes may have additional means of action, but no other mechanisms are presently known. 
Taxanes and Glucose Metabolism 
Taxanes are known to activate TLR4 and several of its downstream signaling 
intermediates, including MyD88 and NFκB (Figure 11) (61). When this pathway is 
stimulated by LPS, cells are desensitized to the apoptotic effects of taxanes (60). Taxanes 
also mimic many of the other effects of LPS, including stimulation of cytokines such as 
TNFα, activation of myeloid associated protein kinases, and up-regulation of LPS-induced 
genes (61). 
Preliminary evidence suggests that taxanes may decrease glucose metabolism in 
cancer patients and in cultured breast cancer cells. If taxanes diminish the availability of 
glucose, this could further affect tumors more deleteriously than normal tissue by starving the 
rapidly dividing cancer cells of energy. 
Importance of a Biomarker for Glucose Metabolism in Cancer Therapy 
If the effectiveness of taxanes depends on glucose metabolism, the variable responses 
of  cancer  patients  to  taxanes  suggest  that  a  biomarker  of  glucose  metabolism  may  be 
necessary to predict whether the drugs will be effective in an individual. Directly measuring 
circulating glucose or insulin may not be useful because they are strongly influenced by 
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FIGURE 11. Liver cell model of the TLR4 pathway. We have shown that this pathway 
inhibits glucose production and utilization when stimulated with lipopolysaccharide in mice 
and in MCF7 cells in culture. Taxanes activate several of the components of this pathway, 
including TLR4, MyD88 and NFκB. Other intermediates are shown faded. By this pathway, 
taxanes could lower glucose availability as a means of exhibiting chemotherapeutic effects. 
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short-term factors such as diet, and they fluctuate diurnally. Additionally, the production and 
utilization of glucose may be more predictive of outcome than are absolute glucose levels. 
Thus, a more stable biomarker that is indicative of glucose turnover is necessary. 
Adiponectin as a Biomarker 
Adiponectin, a peptide hormone secreted from adipose tissue, is inversely correlated 
with glucose production and utilization (39). Levels of adiponectin in circulation are 
dependent upon the size and abundance of slow-growing adipocytes. This makes it a better 
biomarker for glucose metabolism than glucose or insulin, which show diurnal variation and 
are quickly modified by eating patterns and acute stress. 
We hypothesize that elevated adiponectin may predict improved tumor regression in 
cancer patients after treatment with taxanes. Epidemiologic evidence supports the theory that 
adiponectin may have a protective effect against breast cancer (62-66). Additionally, 
adipocyte-secreted factors can affect mammary tumorigenesis by regulating apoptotic 
transcriptional programs (67). Taken together, these data support adiponectin as a potential 
biomarker for the effectiveness of taxanes on cancer. 
Summary 
As chemotherapeutic agents, taxanes may cause cancer regression by starving tumors 
of glucose necessary for survival (Figure 12). Adiponectin is a good biomarker for glucose 
metabolism and may predict the outcomes of cancer patients on taxanes and other 
chemotherapy. We determined (1) whether plasma adiponectin levels increase in response to 
Taxol treatment in breast cancer patients; (2) whether exposure to Taxol decreases glucose 
utilization in MCF7 breast cancer cells; and (3) whether mice bearing MCF7 tumor 
xenografts  could  be  used  as a model to study the effects of taxanes on glucose metabolism. 
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Taxanes 
 Glucose Production 
(  Adiponectin) 
Tumor Growth 
 
 
FIGURE 12. Hypothesized effects of taxane treatment on glucose metabolism and tumor 
growth. Taxanes may lower glucose utilization in vitro, which can be represented by an 
increase in circulating adiponectin in vivo. This effect could play a role in tumor regression in 
some cancer patients who receive taxanes. 
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These studies will provide a better understanding of the role of glucose metabolism in cancer 
progression. Variation in adiponectin levels among individuals could explain the differential 
responses to chemotherapy with taxanes, allowing better prediction of individual outcomes. 
Furthermore, a reduction of adiponectin and subsequent elevation of  the rate of glucose 
metabolism may link obesity and breast cancer. 
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DISCUSSION 
 
Plasma Adiponectin is Associated with Tumor Regression In Patients on Taxol 
 Results were omitted from this thesis due to conflicting publication concerns. 
However, preliminary experiments suggest that positive response (tumor regression) to Taxol 
therapy may be associated with increased plasma adiponectin 24-48 hours after treatment in 
breast cancer patients. The viability of cancer cells is highly dependent on glucose plasma. 
Adiponectin is associated with low fasting glucose utilization (39,68). Low fasting glucose 
utilization may arise from adiponectin inhibition of endogenous glucose production (69). 
Some of the therapeutic effects of taxanes may be mediated by the reduction of glucose 
production and utilization. The investigation of a potentially novel mechanism for 
antineoplastic properties of taxanes may improve our ability to appropriately select patients 
for therapy, optimize delivery of therapy, and provide insight into mechanisms of taxane 
resistance. The mechanism of increased cancer risk in obesity may be mediated by an 
increase in glucose production or directly through adiponectin. 
Taxol Decreases Glucose Utilization in Breast Cancer Cells 
 Preliminary findings suggest that high concentrations of Taxol may be correlated with 
decreased glucose utilization in MCF7 breast cancer cells. LPS lowers glucose utilization 
through TLR4. TLR4 has also been reported to mediate certain effects of taxanes, 
specifically those of paclitaxel, which is commercially distributed as Taxol or Abraxane (61). 
TLR4 may represent the common signaling component for LPS and taxanes in the reduction 
of glucose utilization. Since taxanes are also known to induce apoptosis through microtubule 
hyperstabilization, it is possible that decreased glucose utilization after Taxol exposure is an 
indirect result of cell cycle arrest. Taxol also visibly induced apoptosis in MCF7 cells. 
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Reduction of glucose utilization by taxanes may contribute to growth arrest and apoptosis in 
breast cancer cells. If taxanes lower glucose utilization in human breast cancer cells, then the 
elevation of whole-body fasting glucose utilization may link the increase in the risk of breast 
cancer with obesity and diabetes. Specific markers of apoptosis will be used to quantify cell 
death in future studies. 
Xenografted Mice Are A Model For Studying Glucose Metabolism in Tumors 
Mice bearing MCF7 xenografted tumors are useful models for evaluating the effects 
of taxanes and other chemotherapeutic agents on tumor glucose metabolism. If the injection 
of Taxol lowers whole-body glucose utilization in tumor-bearing mice, then the reduction of 
whole-body fasting glucose utilization with Taxol treatment may be associated with better 
prognosis in breast cancer patients. These data would support the development of ancillary 
dietary or drug interventions targeted at the reduction of glucose utilization. 
Summary 
 As chemotherapeutic agents, taxanes may cause cancer regression by starving tumors 
of glucose necessary for survival. We therefore studied whether taxanes lower glucose 
utilization in human cancer cells and in mice bearing human tumors and to determine 
whether the clinical outcomes of cancer patients on taxanes are correlated with decreased 
glucose utilization and, thus, elevated adiponectin. Although these studies are preliminary, 
they provide a better understanding of the role of glucose metabolism in cancer progression 
and may allow better prediction of individual outcomes. Furthermore, a reduction of 
adiponectin and subsequent elevation of glucose metabolism may link obesity and breast 
cancer. 
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EXPERIMENTAL PROCEDURES 
 
Patients 
LCCC 9819 is an ongoing clinical trial at the UNC Lineberger Comprehensive 
Cancer Center started in 1999.  Plasma samples, tumor specimens and genomic DNA were 
collected from patients with breast cancer undergoing neoadjuvant chemotherapy. Plasma 
samples from 81 breast cancer patients on neoadjuvant Taxol therapy are currently available 
in LCCC 9819. The study was designed to address the question of how the efficacy of the 
monoclonal antibody Herceptin is altered by varying levels of HER2/neu protein expression 
or of gene amplification.  The patient pool has been analyzed for markers of genomic 
stability, proliferative index, apoptosis, and both protein expression and gene amplification of 
the transmembrane receptor HER2/neu, the target of the Herceptin antibody. 
Subjects enrolled had gene amplification of HER2/neu and genes responsible for 
initiation or inhibition of apoptosis, such as p53, bcl-2/bax, and NFκB. The neoadjuvant 
chemotherapy regimen was four cycles of doxorubicin (Adriamycin) and cyclophosphamide, 
termed 4AC, given intravenously every three weeks, followed by 12 weeks of paclitaxel 
(Taxol) accompanied by Herceptin.  The patients then underwent lumpectomy or mastectomy 
for the primary tumor. Plasma samples were obtained prior to any chemotherapy and after 
the first regimens of sequential regimens. 
Blood Collection 
 At least four core biopsy samples (half formalin-fixed, half frozen) plus one 10cc red 
top tube of whole blood were collected. The exact number obtained depended on patient 
tolerance for the procedures. Enrolled patients were admitted to the GCRC for clinical and 
radiographic tumor measurements after diagnosis and again after subsequent regimens, but 
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before Taxol-containing chemotherapy regimens.  Samples and measurements were collected 
no more than four weeks prior to initiation of neoadjuvant chemotherapy. Samples were 
stored at -70°C in the UNC-LCCC Tissue Procurement and Analysis Core Facility.  For 
those patients receiving two different neoadjuvant regimens, for example 4AC followed by 
taxane-based neoadjuvant chemotherapy on LCCC 9818, samples and tumor measurements 
were collected after completion of the initial neoadjuvant chemotherapy (e.g. 4AC) but prior 
to initiation of subsequent (e.g. taxane-based) neoadjuvant chemotherapy. Radiographic 
studies and clinical tumor measurements were performed just prior to the planned definitive 
surgery. 
Evaluation of Pathologic Response 
Stage II-IV breast cancer patients on neoadjuvant Taxol therapy from LCCC 9819 
were used. Patients were segregated into 2 groups – responders and nonresponders – based 
on whether tumor shrinkage occurred. Tumor shrinkage is based on clinical criteria 
(mammogram, ultrasound, medical exam and pathologic response at the time of surgery). 
Pathologic response is a valid predictor of long-term survival (70). Controls were included 
for variability in response assessment and assays used, non-uniform use of surgery, 
unconventional chemotherapeutic regimens and lack of data regarding the amount of 
chemotherapy actually administered, and poor correlation between clinical response and 
pathological response. 
Glucose Utilization in vitro 
MCF7 cells were cultured in Minimal Essential Medium alpha (Gibco) with 10% 
fetal bovine serum, 1% penicillin/streptomycin, 1% sodium pyruvate, and 30 µL/L insulin 
(standard media) until 30-40% confluence. Standard media was removed and replaced with 
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MEM alpha containing 0, 0.01, 0.1, 1.0, or 10 µM Taxol (pharmacological dose is 
approximately 0.1-1.0 µM) in addition to the above ingredients for 0, 1, 2, 4, 8, or 16 hours, 
each in triplicate in 12-well plates. Cells were not allowed to surpass 100% confluence. 
Glucose utilization in MCF7 cells was determined as previously described (39). 
Briefly, cells were split into 12-well plates at a density of 2.5 x 104 cells/well. Media and cell 
lysates were collected separately. Colorimetric assay kits were used to determine glucose in 
the media (Waco) and cell protein content (Lowry). 
Xenografting 
3T3-L1 mouse fibroblasts were used as scaffolding for MCF7 xenografts. Cells were 
grown in insulin-free Dulbecco’s Modifed Eagle’s Medium (high glucose with L-glutamine 
and 110 mg/L sodium pyruvate) (Gibco) containing 10% calf serum and 1% 
penicillin/streptomycin. Cells were not allowed to surpass 100% confluence. 
MCF7 and 3T3-L1 cells were harvested by washing twice with phosphate buffered 
saline followed by trypsinizing for 5 minutes and combined in a single tube at 1 x 104 and 3 x 
105 cells per 100 uL, respectively. The entire 100 uL mixture was injected subcutaneously on 
the back of immunodeficient NOD/scid mice and allowed to grow into single tumors for 6-12 
weeks. 
Western Blots 
Plasma adiponectin was measured in singlet or duplicate by Western blot as 
previously described (71). Briefly, plasma samples were loaded on an SDS gel, transferred to 
a protein membrane and exposed to mouse anti-human adiponectin primary and 125-iodine 
labeled rabbit anti-mouse secondary antibodies. Adiponectin concentration was quantified by 
phosphoimaging. Although adiponectin is found in various multimers in circulation, all 
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adiponectin multimers were denatured by DTT prior to loading and banding appears at 30 
kD. 
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APPENDIX 
 
 The data collected on the effects of taxanes on glucose metabolism are preliminary. In 
addition to conducting more exhaustive experiments, further evaluation of existing data will 
be performed. Some details of these evaluations follows. 
Measuring Baseline Values of Adiponectin 
In addition to comparing post-treatment adiponectin values, we will compare 
differences before and after treatment to determine whether complete or incomplete 
responders show a greater change in adiponectin. In other words, we will determine whether 
there is an effect after adjusting for baseline adiponectin. 
Data Analysis and Interpretation  
Logistic regression models will provide as useful framework for evaluating and 
interpreting associations between adiponectin and the various potentially confounding 
variables such as time after Taxol treatment, multiple chemotherapy treatments and patient 
population heterogeneity. The outcome variable in these models will be a binary indicator of 
50% or greater reduction in tumor size.  The explanatory variables in these models will 
include selected markers.   
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